Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma
CRL抑制剂MLN4924对NF2突变型间皮瘤的治疗效果
基本信息
- 批准号:9028689
- 负责人:
- 金额:$ 52.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-01-01 至 2016-09-30
- 项目状态:已结题
- 来源:
- 关键词:AgarBindingCDKN2A geneCell NucleusCell ProliferationCell SurvivalCellsChemotherapy-Oncologic ProcedureCisplatinClinicClinicalClinical TrialsContact InhibitionCullin ProteinsDNA RepairDevelopmentDrug effect disorderEnzymesExhibitsExtracellular MatrixGene ExpressionGenetically Engineered MouseGrowthImageImmunoblottingIn VitroInstitutionLigaseMaintenanceMalignant Mesothelioma of PeritoneumMalignant NeoplasmsMalignant mesotheliomaMediatingMesotheliomaMessenger RNAModelingMolecularMonitorMusMutationNeurofibromatosis 2Neurofibromin 2NuclearOncogenicOrganoidsOutputPathway interactionsPatientsPemetrexedPharmaceutical PreparationsPhase I/II TrialPhosphotransferasesPleuralPleural cavityPreclinical TestingProliferatingProteinsRegimenRepressionSafetySamplingSignal PathwaySignal TransductionSiteSubfamily lentivirinaeTP53 geneTertiary Protein StructureTestingTherapeuticTranscription CoactivatorTranscriptional ActivationTreatment EfficacyTumor Suppressor GenesTumor Suppressor ProteinsTumor VolumeUbiquitinUbiquitin Like ProteinsXenograft ModelXenograft procedurebasecancer stem cellchemotherapychromatin remodelingclinical efficacycohortconformerefficacy testingflexibilityimprovedimproved outcomein vivoinhibitor/antagonistmouse modelmutantneoplastic cellnovelnovel therapeuticsp19ARFphase I trialphase II trialpre-clinicalpreclinical efficacypreclinical studypublic health relevanceresearch clinical testingsmall hairpin RNAsmall moleculetumortumor growthtumorigenesisubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): Patients with advanced malignant mesothelioma (MM) have limited treatment options. The standard first-line chemotherapy regimen, pemetrexed/cisplatin, improves survival compared to cisplatin alone from 9 to 12 months. In order to develop mechanism-based therapies for MM, it is important to identify the oncogenic mutations and signaling pathways that drive its development and sustain its maintenance. Although about 75% of MM carry mutations at the NF2 locus, which encodes Merlin. We have discovered that inactivation of Merlin drives the development and maintenance of MM by activating the pro-oncogenic E3 ubiquitin Cullin Ring Ligase CRL4DCAF1, which in turn inhibits the Hippo pathway tumor suppressor kinases Lats1/2. Our Preliminary Studies indicate that the CRL inhibitor MLN4924, developed by Millenium-Takeda, exhibits exhibit selective preclinical efficacy in NF2 mutant MM cells. In addition, in vitro and in vivo studies indicate that MLN4924 significantly enhances the efficacy of pemetrexed and cisplatin in NF2 mutant MM. To establish the pre-clinical and clinical activity of MLN4924, alone and in combination with chemotherapy, in NF2 mutant MM, we will pursue the following independent, but interrelated Specific Aims: 1) To test the preclinical activity of MLN4924, alone and in combination with chemotherapy, in a novel Genetically Engineered Mouse Model (GEMM) of MM. Nf2Flox/Flox; LucR mice will be injected in their pleural cavity with lentiviruses encoding Cre in combination with short hairpin (sh) RNAs targeting the mRNAs encoded by Cdkn2a or both Cdkn2a and Bap1. Tumor-bearing mice will be treated with MLN4924, pemetrexed/cisplatinum, or both and subjected to bioluminescent imaging to monitor tumor growth. Molecular studies on tumor samples will enable us to verify target inhibition and to determine the mechanism of action of MLN4924. 2) To test the preclinical efficacy of MLN4924, alone and in combination with chemotherapy, in patient-derived xenograft (PDX) models of MPM. PDX models of MMs carrying mutations at the NF2 locus, the BAP1 locus, or at both loci will be treated with MLN4924, alone and in combination with cispatin/pemetrexed, and the results will be examined as described above. The sensitivity of prospectively isolated cancer stem cells to the drugs will be examined in tumor organoid cultures. 3) To test the clinical efficacy of MLN4924 by conducting a phase I/II trial in patients with pleural or peritoneal MM. We will conduct a single institution trial comprising two cohorts: 1 a phase II trial of single agent MLN4924 in patients with NF2 mutant MM, and 2) a phase I trial combining MLN4924 with pemetrexed/cisplatin in previously untreated patients. Information gained from pre-clinical studies in the newly developed GEMM model and state-of-the-art PDX models will help to refine the analysis of patient samples from the clinical trial and, conversely,
information gained from the clinical trial will motivate additional pre-clinical studies. We envisin that mechanism-based therapies, such as the one proposed here, will radically improve the outcome of patients with MM.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FILIPPO G GIANCOTTI其他文献
FILIPPO G GIANCOTTI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FILIPPO G GIANCOTTI', 18)}}的其他基金
Mechanisms governing metastatic dormancy and reactivation
控制转移休眠和重新激活的机制
- 批准号:
9324199 - 财政年份:2016
- 资助金额:
$ 52.54万 - 项目类别:
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma
CRL抑制剂MLN4924对NF2突变型间皮瘤的治疗效果
- 批准号:
10542988 - 财政年份:2016
- 资助金额:
$ 52.54万 - 项目类别:
Mechanisms governing metastatic dormancy and reactivation
控制转移休眠和重新激活的机制
- 批准号:
8956183 - 财政年份:2016
- 资助金额:
$ 52.54万 - 项目类别:
Mechanisms governing metastatic dormancy and reactivation
控制转移休眠和重新激活的机制
- 批准号:
10227143 - 财政年份:2016
- 资助金额:
$ 52.54万 - 项目类别:
Mechanisms governing metastatic dormancy and reactivation
控制转移休眠和重新激活的机制
- 批准号:
10474409 - 财政年份:2016
- 资助金额:
$ 52.54万 - 项目类别:
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma
CRL抑制剂MLN4924对NF2突变型间皮瘤的治疗效果
- 批准号:
10004502 - 财政年份:2016
- 资助金额:
$ 52.54万 - 项目类别:
Mechanisms governing metastatic dormancy and reactivation
控制转移休眠和重新激活的机制
- 批准号:
9982048 - 财政年份:2016
- 资助金额:
$ 52.54万 - 项目类别:
Mechanisms governing metastatic dormancy and reactivation
控制转移休眠和重新激活的机制
- 批准号:
10474923 - 财政年份:2016
- 资助金额:
$ 52.54万 - 项目类别:
Mechanisms governing metastatic dormancy and reactivation
控制转移休眠和重新激活的机制
- 批准号:
9751221 - 财政年份:2016
- 资助金额:
$ 52.54万 - 项目类别:
Mechanisms governing metastatic reactivation of breast cancer.
控制乳腺癌转移再激活的机制。
- 批准号:
8642161 - 财政年份:2013
- 资助金额:
$ 52.54万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Continuing Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Standard Grant
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Research Grant
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Fellowship
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Discovery Projects
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Research Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Discovery Projects